top of page
![origenis_logo_Pantone [Konvertiert]_2020](https://static.wixstatic.com/media/9afeac_83ea95f8f63144538d48a310b96d7f33~mv2.png/v1/fill/w_260,h_53,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/origenis_logo_Pantone%20%5BKonvertiert%5D_2020.png){kind=logo}
Press releases
Reaching new heights
Press releases
Reaching new heights
Origenis presents preclinical data for ORI-15412, a novel, fully brain penetrant CDK9 inhibitor at the AACR in Chicago
Origenis presents preclinical data for ORI-15412, a novel, fully brain penetrant CDK9 inhibitor at the AACR in Chicago. Two posters are...
-
vor 6 Stunden1 Min. Lesezeit
10
ONCOBONE VENTURES AND ORIGENIS ANNOUNCE PARTNERSHIP TO DEVELOP NOVEL THERAPIES FOR CANCER BONE METASTASIS
London, UK – OncoBone Ventures Ltd, based in the UK, and Origenis GmbH, headquartered in Planegg, Germany, have signed a Framework Agreement
-
28. Mai 20241 Min. Lesezeit
1.511
Neue Niedermolekulare Medikamente der Zukunft für das ZNS
Die Origenis nutzt ihre AI-Technologieplattform, um hochoptimierte Wirkstoffe für neurodegenerative, neuroonkologische und...
-
15. März 20241 Min. Lesezeit
2.052
bottom of page